SG10201910522TA - Improved uricase sequences and methods of treatment - Google Patents
Improved uricase sequences and methods of treatmentInfo
- Publication number
- SG10201910522TA SG10201910522TA SG10201910522TA SG10201910522TA SG10201910522TA SG 10201910522T A SG10201910522T A SG 10201910522TA SG 10201910522T A SG10201910522T A SG 10201910522TA SG 10201910522T A SG10201910522T A SG 10201910522TA SG 10201910522T A SG10201910522T A SG 10201910522TA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- methods
- uricase sequences
- improved
- improved uricase
- Prior art date
Links
- 108010092464 Urate Oxidase Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12N9/0048—Uricase (1.7.3.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562162280P | 2015-05-15 | 2015-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201910522TA true SG10201910522TA (en) | 2020-01-30 |
Family
ID=57320301
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201910522TA SG10201910522TA (en) | 2015-05-15 | 2016-05-13 | Improved uricase sequences and methods of treatment |
| SG11201708759YA SG11201708759YA (en) | 2015-05-15 | 2016-05-13 | Improved uricase sequences and methods of treatment |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201708759YA SG11201708759YA (en) | 2015-05-15 | 2016-05-13 | Improved uricase sequences and methods of treatment |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11098289B2 (enExample) |
| EP (1) | EP3294322A4 (enExample) |
| JP (2) | JP2018515101A (enExample) |
| KR (1) | KR20180002828A (enExample) |
| CN (1) | CN107614007B (enExample) |
| AU (2) | AU2016265677B2 (enExample) |
| BR (1) | BR112017024212A2 (enExample) |
| CA (1) | CA2984926A1 (enExample) |
| CL (1) | CL2017002774A1 (enExample) |
| CO (1) | CO2017012454A2 (enExample) |
| HK (1) | HK1252542A1 (enExample) |
| IL (1) | IL255403A0 (enExample) |
| MX (1) | MX2017014547A (enExample) |
| MY (1) | MY190411A (enExample) |
| RU (1) | RU2752497C2 (enExample) |
| SG (2) | SG10201910522TA (enExample) |
| WO (1) | WO2016187026A1 (enExample) |
| ZA (1) | ZA201708507B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201910522TA (en) | 2015-05-15 | 2020-01-30 | Medimmune Llc | Improved uricase sequences and methods of treatment |
| CN106554948B (zh) * | 2015-09-29 | 2019-06-25 | 上海生物制品研究所有限责任公司 | 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用 |
| CN112410313A (zh) * | 2019-08-20 | 2021-02-26 | 中国科学院上海药物研究所 | 一种高热稳定性尿酸酶及其应用 |
| CN112646790A (zh) * | 2019-10-11 | 2021-04-13 | 上海君实生物医药科技股份有限公司 | 改进的尿酸酶及其用于治疗高尿酸血症的方法 |
| WO2021083278A1 (en) * | 2019-10-29 | 2021-05-06 | Westlake Therapeutics (Hangzhou) Co. Limited | Engineering red blood cells for treating gout and hyperuricemia diseases |
| KR20230059777A (ko) | 2020-09-25 | 2023-05-03 | 주식회사 프로앱텍 | 요산산화효소-알부민 접합체, 그 제조방법 및 용도 |
| WO2022081774A1 (en) * | 2020-10-13 | 2022-04-21 | University Of Florida Research Foundation, Incorporated | Self-assembling uricase fusion peptides |
| JP2023548496A (ja) | 2020-11-03 | 2023-11-17 | プロタリクス リミテッド | 修飾ウリカーゼ及びその使用 |
| CN114438048B (zh) * | 2020-11-05 | 2024-10-22 | 重庆派金生物科技有限公司 | 尿酸氧化酶制剂及其应用 |
| CN115197923B (zh) * | 2021-04-09 | 2024-11-26 | 上海君实生物医药科技股份有限公司 | 尿酸酶、其药物组合物及其用途 |
| KR20240049312A (ko) * | 2021-07-08 | 2024-04-16 | 주식회사 프로앱텍 | Arthrobacter globiformis 유래 요산산화효소-알부민 접합체, 그 제조방법 및 그 용도 |
| KR20240083169A (ko) * | 2021-09-23 | 2024-06-11 | 주식회사 프로앱텍 | Apn 그룹을 포함하는 링커 및 이를 이용하여 제조된 기능성 폴리펩티드 변이체-알부민 컨쥬게이트 |
| US20250241999A1 (en) * | 2021-10-15 | 2025-07-31 | Georgia State University Research Foundation, Inc. | Delivery of therapeutic recombinant uricase using nanoparticles |
| CN119752761B (zh) * | 2025-03-07 | 2025-06-17 | 北京化工大学 | 一种高产heparosan的基因工程菌及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09154581A (ja) * | 1995-12-05 | 1997-06-17 | Asahi Chem Ind Co Ltd | ウリカーゼを生産する実質上純粋な微生物 |
| US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| ATE498409T1 (de) * | 1998-08-06 | 2011-03-15 | Mountain View Pharmaceuticals | Peg-uricase konjugate und verwendung davon |
| RU2290439C2 (ru) | 1998-08-06 | 2006-12-27 | Дьюк Юниверсити | Рекомбинантный белок уриказы млекопитающего для конъюгирования с пэг, молекула нуклеиновой кислоты, кодирующая его, вектор для его экспрессии, способ его получения и применение |
| HU228916B1 (en) * | 1998-08-06 | 2013-06-28 | Mountain View Pharmaceuticals | Polyethylen-glycol/carbamate oxydase conjugates and pharmaceutical compositions containing thereof |
| NZ513077A (en) * | 1999-01-14 | 2004-03-26 | Bolder Biotechnology Inc | Methods for making proteins containing free cysteine residues |
| US6913915B2 (en) * | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
| SG10201706384VA (en) * | 2005-04-11 | 2017-09-28 | Crealta Pharmaceuticals Llc | A variant form of urate oxidase and use thereof |
| NZ562292A (en) * | 2005-04-11 | 2009-11-27 | Savient Pharmaceuticals Inc | Variant forms of urate oxidase and use thereof |
| US8148123B2 (en) | 2005-04-11 | 2012-04-03 | Savient Pharmaceuticals, Inc. | Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase |
| US20130305398A1 (en) * | 2012-02-16 | 2013-11-14 | Marie Coffin | Genes and uses for plant enhacement |
| DK2840142T3 (en) * | 2007-06-06 | 2019-03-18 | Monsanto Technology Llc | Genes and uses for plant improvement |
| KR101861547B1 (ko) | 2009-06-25 | 2018-07-02 | 크레알타 파마슈티칼스 엘엘씨 | 페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체매개 상실을 예측하는 방법 및 키트 |
| CN103184208B (zh) * | 2011-12-27 | 2015-09-16 | 拜奥生物科技（上海）有限公司 | 人精氨酸酶和定点聚乙二醇化人精氨酸酶及其应用 |
| SG10201910522TA (en) | 2015-05-15 | 2020-01-30 | Medimmune Llc | Improved uricase sequences and methods of treatment |
-
2016
- 2016-05-13 SG SG10201910522TA patent/SG10201910522TA/en unknown
- 2016-05-13 SG SG11201708759YA patent/SG11201708759YA/en unknown
- 2016-05-13 CA CA2984926A patent/CA2984926A1/en active Pending
- 2016-05-13 AU AU2016265677A patent/AU2016265677B2/en not_active Ceased
- 2016-05-13 BR BR112017024212A patent/BR112017024212A2/pt not_active IP Right Cessation
- 2016-05-13 RU RU2017143580A patent/RU2752497C2/ru active
- 2016-05-13 WO PCT/US2016/032415 patent/WO2016187026A1/en not_active Ceased
- 2016-05-13 JP JP2017559314A patent/JP2018515101A/ja active Pending
- 2016-05-13 EP EP16797021.9A patent/EP3294322A4/en not_active Withdrawn
- 2016-05-13 HK HK18111855.1A patent/HK1252542A1/zh unknown
- 2016-05-13 KR KR1020177035108A patent/KR20180002828A/ko not_active Ceased
- 2016-05-13 MX MX2017014547A patent/MX2017014547A/es unknown
- 2016-05-13 CN CN201680027432.9A patent/CN107614007B/zh not_active Expired - Fee Related
- 2016-05-13 US US15/573,993 patent/US11098289B2/en active Active
- 2016-05-13 MY MYPI2017704267A patent/MY190411A/en unknown
-
2017
- 2017-11-02 IL IL255403A patent/IL255403A0/en unknown
- 2017-11-03 CL CL2017002774A patent/CL2017002774A1/es unknown
- 2017-12-01 CO CONC2017/0012454A patent/CO2017012454A2/es unknown
- 2017-12-14 ZA ZA2017/08507A patent/ZA201708507B/en unknown
-
2018
- 2018-10-23 US US16/167,765 patent/US10883087B2/en active Active
-
2020
- 2020-11-18 US US16/951,764 patent/US20210254024A1/en not_active Abandoned
-
2021
- 2021-08-06 JP JP2021130287A patent/JP2021184733A/ja active Pending
-
2022
- 2022-01-10 AU AU2022200104A patent/AU2022200104A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2752497C2 (ru) | 2021-07-28 |
| EP3294322A4 (en) | 2018-12-12 |
| US11098289B2 (en) | 2021-08-24 |
| RU2017143580A3 (enExample) | 2019-12-16 |
| CA2984926A1 (en) | 2016-11-24 |
| CN107614007B (zh) | 2022-03-25 |
| BR112017024212A2 (pt) | 2018-07-17 |
| CL2017002774A1 (es) | 2018-04-06 |
| AU2022200104A1 (en) | 2022-02-03 |
| WO2016187026A1 (en) | 2016-11-24 |
| IL255403A0 (en) | 2017-12-31 |
| MY190411A (en) | 2022-04-21 |
| US20210254024A1 (en) | 2021-08-19 |
| CN107614007A (zh) | 2018-01-19 |
| AU2016265677A1 (en) | 2018-01-04 |
| CO2017012454A2 (es) | 2018-04-30 |
| AU2016265677B2 (en) | 2021-12-09 |
| RU2017143580A (ru) | 2019-06-17 |
| EP3294322A1 (en) | 2018-03-21 |
| KR20180002828A (ko) | 2018-01-08 |
| JP2018515101A (ja) | 2018-06-14 |
| JP2021184733A (ja) | 2021-12-09 |
| US20180258406A1 (en) | 2018-09-13 |
| HK1252542A1 (zh) | 2019-05-31 |
| US10883087B2 (en) | 2021-01-05 |
| US20190048327A1 (en) | 2019-02-14 |
| MX2017014547A (es) | 2018-03-15 |
| SG11201708759YA (en) | 2017-11-29 |
| ZA201708507B (en) | 2018-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006746B (en) | Methods of treatment | |
| ZA201708507B (en) | Improved uricase sequences and methods of treatment | |
| IL274865A (en) | Treatment methods with asparaginase | |
| SI3285777T1 (sl) | Glikanski terapevtiki in postopki zdravljenja | |
| IL282482A (en) | Variants of protoxin-II and methods of use | |
| ZA201706059B (en) | Method of treatment with tradipitant | |
| IL265359A (en) | Modified Oligonucleotides and Methods of Use | |
| IL282508A (en) | Variants of protoxin-II and methods of use | |
| EP3684342C0 (en) | TREATMENT PROCEDURES | |
| PL3183003T3 (pl) | SPOSOBY ZAPOBIEGANIA l/LUB LECZENIA ZAKAŻENIA | |
| GB201706406D0 (en) | Method of treatment | |
| GB201815588D0 (en) | Method of treatment | |
| IL254825A0 (en) | Methods of treatment with Tesalisib | |
| ZA201705847B (en) | Treatment of pain | |
| EP3134108A4 (en) | Agents and methods of treatment | |
| GB201416832D0 (en) | Methods of treatment | |
| GB201511799D0 (en) | Composition and methods of treatment | |
| SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
| GB201621737D0 (en) | Compositions and methods of treatment | |
| GB201602802D0 (en) | Method of treatment | |
| GB201605127D0 (en) | Composition and methods of treatment | |
| GB201417248D0 (en) | Compostion and methods of treatment | |
| ZA201802201B (en) | Novel formulation and treatment methods | |
| GB201512139D0 (en) | Methods of treatment | |
| GB201720439D0 (en) | Method of treatment |